<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">METRONIDAZOLE <img border="0" src="../images/pr.gif"/></span><br/>(me-troe-ni'da-zole)<br/><span class="topboxtradename">Flagyl, </span><span class="topboxtradename">Flagyl ER, </span><span class="topboxtradename">Flagyl IV RTU, </span><span class="topboxtradename">Flagyl 375, </span><span class="topboxtradename">Metizol, </span><span class="topboxtradename">Metric 21, </span><span class="topboxtradename">Metro I.V., </span><span class="topboxtradename">MetroGel, </span><span class="topboxtradename">MetroGel Vaginal, </span><span class="topboxtradename">MetroLotion, </span><span class="topboxtradename">Noritate, </span><span class="topboxtradename">Protostat<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antitrichomonal</span>; <span class="classification">amebicide</span>; <span class="classification">antibiotic</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg, 500 mg tablets; 375 mg capsules; 750 mg sustained release tablets; 500 mg vials; 0.75% lotion, emulsion; 0.75%, 1% cream; 0.75%, 1% gel</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic compound with direct trichomonacidal and amebicidal activity as well as antibacterial activity against anaerobic
         bacteria and some gram-negative bacteria.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against <i>Trichomonas vaginalis, Entamoeba histolytica,</i> and <i>Giardia lamblia</i>. Exhibits antibacterial activity against obligate anaerobic bacteria, gram-negative anaerobic bacilli, and <i>Clostridia</i>. Microaerophilic <i>Streptococci</i> and most aerobic bacteria are resistant.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Asymptomatic and symptomatic trichomoniasis in females and males; acute intestinal amebiasis and amebic liver abscess; preoperative
         prophylaxis in colorectal surgery, elective hysterectomy or vaginal repair, and emergency appendectomy. IV metronidazole is
         used for the treatment of serious infections caused by susceptible anaerobic bacteria in intraabdominal infections, skin infections,
         gynecologic infections, septicemia, and for both pre- and postoperative prophylaxis, bacterial vaginosis. <i>Topical:</i> Rosacea.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of pseudomembranous colitis, Crohn's disease, <i>H. pylori</i> eradication.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Blood dyscrasias; active CNS disease; first trimester of pregnancy (category B), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Coexistent candidiasis; second and third trimesters of pregnancy (category B); alcoholism; liver disease.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Trichomoniasis, Giardiasis, <i>Gardnerella</i>
</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2 g once or 250 mg t.i.d.; 375 mg b.i.d. or 500 mg b.i.d. for 7 d <span class="rdroute">Vaginal</span> Apply once or twice daily times 5 d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 15 mg/kg/d in 3 divided doses for 710 d<br/><span class="rdage">Infant:</span> <span class="rdroute">PO</span> 1030 mg/kg/d for 58 d<br/><br/><span class="indicationtitle">Amebiasis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 500750 mg t.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 3550 mg/kg/d in 3 divided doses<br/><br/><span class="indicationtitle">Anaerobic Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 7.5 mg/kg q6h (max: 4 g/d) <span class="rdroute">IV Loading Dose</span> 15 mg/kg <span class="rdroute">IV Maintenance Dose</span> 7.5 mg/kg q6h (max: 4 g/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IV</span> 30 mg/kg/d divided q6h (max: 4 g/d)<br/><span class="rdage">Neonate:</span> <span class="rdroute">PO/IV</span> 7.515 mg/kg/d divided q1248h<br/><br/><span class="indicationtitle">Pseudomembranous Colitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 250500 mg t.i.d. <span class="rdroute">IV</span> 250500 mg t.i.d. or q.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 30 mg/kg/d divided q6h times 7 d<br/><br/><span class="indicationtitle">Bacterial Vaginosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> (Flagyl ER) 750 mg q.d. times 7 d<br/><br/><span class="indicationtitle">Rosacea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> Apply 0.75% gel as a thin film to affected area b.i.d.; apply 1% gel as a thin film to affected area q.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Crush tablets before ingestion if patient cannot swallow whole.</li>
<li>Ensure that Flagyl ER (extend-release form) is not chewed or crushed. It must be swallowed whole. Give on an empty stomach,
            1 h before or 2 h after meals.
         </li>
<li>Give immediately before, with, or immediately after meals or with food or milk to reduce GI distress.</li>
<li>Give lower than normal doses in presence of liver disease.</li>
</ul><span class="adminroutetype">Topical</span><br/><ul>
<li>Apply a thin film to affected area only.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>
                     					Note: Verify correct IV concentration and rate of infusion for administration to neonates, infants, or children with physician.
                     				
                  </li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span> Sequence for preparing solution (important) consists of (1) reconstitution with 4.4 mL sterile water or NS, (2) dilution in
                  IV solution to yield 8 mg/mL in NS, D5W, or RL, (3) pH neutralization with approximately 5 mEq sodium bicarbonate injection
                  for each 500 mg of Flagyl I.V. used. Avoid use of aluminum-containing equipment when manipulating IV product (including syringes
                  equipped with aluminum needles or hubs). Note: Flagyl IV RTU does not require mixing, diluting, or neutralizing. Each container
                  contains 14 mEq of sodium.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Intermittent:</span>  Give IV solution slowly at a rate of one dose per hour.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<span class="classification">tpn</span>, <b>amoxicillin/clavulanate,</b>
<b>aztreonam,</b>
<b>dopamine,</b>
<b>meropenem.</b>
<span class="incompattype"> Y-site:</span>
<b>Amphotericin B cholesteryl complex,</b>
<b>aztreonam,</b>
<b>filgrastim,</b>
<b>meropenem,</b>
<b>warfarin.</b>
</p>
<ul>
<li>
                     						Note: Precipitation occurs if neutralized solution is refrigerated. Use diluted and neutralized solution within 24 h of preparation.
                     					
                  </li>
</ul>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F); protect from light. Reconstituted Flagyl I.V. is chemically
            stable for 96 h when stored below 30° C (86° F) in room light. Diluted and neutralized IV solutions containing Flagyl
            I.V. should be used within 24 h of mixing.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity (rash, urticaria, pruritus, flushing), fever, fleeting joint pains, overgrowth of <span class="speceff-common">Candida</span>. <span class="typehead">CNS:</span> Vertigo, headache, ataxia, confusion, irritability, depression, restlessness, weakness, fatigue, drowsiness, insomnia, paresthesias,
      sensory neuropathy (rare). <span class="typehead">GI:</span>
<span class="speceff-common">Nausea,</span> vomiting, anorexia, epigastric distress, abdominal cramps, diarrhea, constipation, dry mouth, metallic or bitter taste, proctitis. <span class="typehead">Urogenital:</span> Polyuria, dysuria, pyuria, incontinence, cystitis, decreased libido, dyspareunia, dryness of vagina and vulva, sense of pelvic
      pressure. <span class="typehead">Special Senses:</span> Nasal congestion. <span class="typehead">CV:</span> ECG changes (flattening of T wave). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>
<b>Metronidazole</b> may interfere with certain chemical analyses for <span class="alt">AST,</span> resulting in decreased values.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">oral anticoagulants</span> potentiate hypoprothrombinemia; <b>alcohol</b> may elicit disulfiram reaction; oral solutions of <b>citalopram,</b>
<b>ritonavir;</b>
<b>lopinavir/ritonavir,</b> and IV formulations of <b>sulfamethoxazole;</b>
<b>trimethoprim,</b>
<b>SMX-TMP,</b>
<b>nitroglycerin</b> may elicit disulfiram reaction due to the alcohol content of the dosage form; <b>disulfiram</b> causes acute psychosis; <b>phenobarbital</b> increases metronidazole metabolism; may increase <b>lithium</b> levels; <b>fluorouracil,</b>
<b>azathioprine</b> may cause transient neutropenia. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 80% of dose absorbed from GI tract. <span class="typehead">Peak:</span> 13 h. <span class="typehead">Distribution:</span> Widely distributed to most body tissues, including CSF, bone, cerebral and hepatic abscesses; crosses placenta; distributed
      in breast milk. <span class="typehead">Metabolism:</span> 3060% metabolized in liver. <span class="typehead">Elimination:</span> 77% excreted in urine; 14% excreted in feces within 24 h. <span class="typehead">Half-Life:</span> 68 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Discontinue therapy immediately if symptoms of CNS toxicity (see Appendix F) develop. Monitor especially for seizures and
            peripheral neuropathy (e.g., numbness and paresthesia of extremities).
         </li>
<li>Lab tests: Obtain total and differential WBC counts before, during, and after therapy, especially if a second course is necessary.</li>
<li>Monitor for S&amp;S of sodium retention, especially in patients on corticosteroid therapy or with a history of CHF.</li>
<li>Monitor patients on lithium for elevated lithium levels.</li>
<li>Report appearance of candidiasis or its becoming more prominent with therapy to physician promptly.</li>
<li>Repeat feces examinations, usually up to 3 mo, to ensure that amebae have been eliminated.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Adhere closely to the established regimen without schedule interruption or changing the dose.</li>
<li>Refrain from intercourse during therapy for trichomoniasis unless male partner wears a condom to prevent reinfection.</li>
<li>Have sexual partners receive concurrent treatment. Asymptomatic trichomoniasis in the male is a frequent source of reinfection
            of the female.
         </li>
<li>Do not drink alcohol during therapy; may induce a disulfiram-type reaction (see Appendix F). Avoid alcohol or alcohol-containing
            medications for at least 48 h after treatment is completed.
         </li>
<li>Urine may appear dark or reddish brown (especially with higher than recommended doses). This appears to have no clinical significance.</li>
<li>Report symptoms of candidal overgrowth: Furry tongue, color changes of tongue, glossitis, stomatitis; vaginitis, curd-like,
            milky vaginal discharge; proctitis. Treatment with a candidacidal agent may be indicated.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>